Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704921 | 1.00 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL704922 | 1.00 | NR1H2 (0.34) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL28636685 | 0.87 | EPHX2 (0.33) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL22108626 | 0.87 | EPHX2 (0.33) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL16749353 | 0.85 | CHRM2 (0.35) | NR1H2CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL16749562 | 0.85 | CHRM2 (0.35) | NR1H2CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL17924693 | 0.85 | CHRM2 (0.35) | NR1H2CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL15229449 | 0.85 | EPHX2 (0.35) | NR1H2EPHX2DDB1CRBNHSD17B10 | |
| SCHEMBL903369 | 0.83 | NR1H2 (0.35) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL26782338 | 0.83 | NR1H2 (0.35) | NR1H2HDAC8CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3071564-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | NR1H2 3479/4885HDAC8 874/4885CHRM2 1532/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | NR1H2 2667/4885HDAC8 1191/4885CHRM2 1876/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | NR1H2 2527/4885HDAC8 3182/4885CHRM2 1569/4885 |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | NR1H2 781/4885HDAC8 1745/4885CHRM2 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.